Context Right heart catheterisation is the gold standard for the diagnosis of pulmonary hypertension. However, echocardiography is frequently used to screen for this disease and monitor progression ...

Background: The prevalence of portopulmonary hypertension (PPHTN) in patients with cirrhosis and refractory ascites is unknown. Its presence may preclude patients from receiving a transjugular ...

Long-term exposure to particulate matter in patients with pulmonary arterial hypertension increases risk for lung transplantation or death.

Persistent pulmonary hypertension of the newborn (PPHN) is the most common neonatal form and mostly reversible after a few days with improvement of the underlying pulmonary condition. When pulmonary ...

Hypertension (HTN) increases the risk of heart failure (HF) and it precedes it in 75 percent of cases. This article reviews essential HTN treatment in patients at risk for developing HF.

Pulmonary hypertension is a rare, ostensibly incurable, and etiologically diverse disease with an unacceptably high 5-year mortality rate (≈50%), worse than many cancers. Irrespective of pathogenic ...

Patients with pulmonary hypertension associated with congenital heart disease make up an increasing proportion of the total pulmonary hypertension population who bring with them added complexity ...

Objectives To investigate demographic, clinical characteristics, treatment patterns and healthcare resource utilisation (HCRU) among patients with portopulmonary hypertension (PoPH). Design ...

Pulmonary hypertension occurs when there is an abnormally high pressure in the blood vessels between the lungs and the heart.

These models confirmed that exposure to gestational hypertension in the womb increased seizure sensitivity and death due to seizures in offspring.

It may also be effective in select patients with pulmonary arterial hypertension related to collagen vascular disease, congenital heart disease and portopulmonary hypertension. [27, 28 ...

Widaplik is a single tablet, triple combination therapy for hypertension that is expected to be available in the fourth quarter of 2025.